Efficacy of flibanserin in women with hypoactive sexual desire disorder: results from the BEGONIA trial
- PMID: 23672269
- DOI: 10.1111/jsm.12189
Efficacy of flibanserin in women with hypoactive sexual desire disorder: results from the BEGONIA trial
Abstract
Introduction: Hypoactive Sexual Desire Disorder (HSDD) is characterized by low sexual desire that causes marked distress or interpersonal difficulty.
Aim: The aim of this study was to assess the efficacy and safety of the 5-HT1A agonist/5-HT2A antagonist flibanserin in premenopausal women with HSDD.
Methods: This was a randomized, placebo-controlled trial in which premenopausal women with HSDD (mean age: 36.6 years) were treated with flibanserin 100 mg once daily at bedtime (qhs) (n = 542) or placebo (n = 545) for 24 weeks.
Main outcome measures: Coprimary end points were the change from baseline to study end in Female Sexual Function Index (FSFI) desire domain score and in number of satisfying sexual events (SSE) over 28 days. Secondary end points included the change from baseline in FSFI total score, Female Sexual Distress Scale-Revised (FSDS-R) total score, and FSDS-R Item 13 score.
Results: Compared with placebo, flibanserin led to increases in mean (standard deviation) SSE of 2.5 (4.6) vs. 1.5 (4.5), mean (standard error [SE]) FSFI desire domain score of 1.0 (0.1) vs. 0.7 (0.1), and mean (SE) FSFI total score of 5.3 (0.3) vs. 3.5 (0.3); and decreases in mean (SE) FSDS-R Item 13 score of -1.0 (0.1) vs. -0.7 (0.1) and mean (SE) FSDS-R total score of -9.4 (0.6) vs. -6.1 (0.6); all P ≤ 0.0001. The most frequently reported adverse events in the flibanserin group were somnolence, dizziness, and nausea, with adverse events leading to discontinuation in 9.6% of women receiving flibanserin vs. 3.7% on placebo.
Conclusion: In premenopausal women with HSDD, flibanserin 100 mg qhs resulted in significant improvements in the number of SSE and sexual desire (FSFI desire domain score) vs. placebo. Flibanserin was associated with significant reductions in distress associated with sexual dysfunction (FSDS-R total score) and distress associated with low sexual desire (FSDS-R Item 13) vs. placebo. There were no significant safety concerns associated with the use of flibanserin for 24 weeks.
Keywords: Distress; Flibanserin; HSDD; Hypoactive Sexual Desire Disorder; Patient-Reported Outcomes; Premenopausal Women.
© 2013 International Society for Sexual Medicine.
Similar articles
-
Continued efficacy and safety of flibanserin in premenopausal women with Hypoactive Sexual Desire Disorder (HSDD): results from a randomized withdrawal trial.J Sex Med. 2011 Nov;8(11):3160-72. doi: 10.1111/j.1743-6109.2011.02458.x. Epub 2011 Sep 20. J Sex Med. 2011. PMID: 21933348 Clinical Trial.
-
Flibanserin for Premenopausal Hypoactive Sexual Desire Disorder: Pooled Analysis of Clinical Trials.J Womens Health (Larchmt). 2019 Jun;28(6):769-777. doi: 10.1089/jwh.2018.7516. Epub 2019 Feb 1. J Womens Health (Larchmt). 2019. PMID: 30707049
-
Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the VIOLET Study.J Sex Med. 2012 Apr;9(4):1074-85. doi: 10.1111/j.1743-6109.2011.02626.x. Epub 2012 Jan 16. J Sex Med. 2012. PMID: 22248038 Clinical Trial.
-
Efficacy and Safety of Flibanserin in Women with Hypoactive Sexual Desire Disorder: A Systematic Review and Meta-Analysis.J Sex Med. 2015 Nov;12(11):2095-104. doi: 10.1111/jsm.13037. J Sex Med. 2015. PMID: 26745616 Review.
-
Efficacy and Safety of Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Women: A Systematic Review and Meta-analysis.JAMA Intern Med. 2016 Apr;176(4):453-62. doi: 10.1001/jamainternmed.2015.8565. JAMA Intern Med. 2016. PMID: 26927498 Review.
Cited by
-
Melanocortin 4 receptor signaling in Sim1 neurons permits sexual receptivity in female mice.Front Endocrinol (Lausanne). 2023 Mar 24;14:983670. doi: 10.3389/fendo.2023.983670. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37033219 Free PMC article.
-
Female sexual dysfunction: A potential minefield.Indian J Sex Transm Dis AIDS. 2022 Jul-Dec;43(2):128-134. doi: 10.4103/ijstd.IJSTD_82_20. Epub 2022 Nov 17. Indian J Sex Transm Dis AIDS. 2022. PMID: 36743096 Free PMC article. Review.
-
Effects of Flibanserin on Subdomain Scores of the Female Sexual Function Index in Women With Hypoactive Sexual Desire Disorder.Sex Med. 2022 Dec;10(6):100570. doi: 10.1016/j.esxm.2022.100570. Epub 2022 Nov 10. Sex Med. 2022. PMID: 36400683 Free PMC article.
-
Pudendal, but not tibial, nerve stimulation modulates vulvar blood perfusion in anesthetized rodents.Int Urogynecol J. 2023 Jul;34(7):1477-1486. doi: 10.1007/s00192-022-05389-x. Epub 2022 Nov 3. Int Urogynecol J. 2023. PMID: 36326861 Free PMC article.
-
Bremelanotide for Treatment of Female Hypoactive Sexual Desire.Neurol Int. 2022 Jan 4;14(1):75-88. doi: 10.3390/neurolint14010006. Neurol Int. 2022. PMID: 35076581 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical